GENFIT announced some key leadership changes to accompany GENFIT into the next stage of its development and its evolution from an R&D biotechnology company to a fully-integrated biopharmaceutical company. Dean Hum has been appointed Deputy CEO. Dean will bring to this new role his demonstrated ability to address key corporate challenges, ranging from financial transactions to corporate strategy, and including human resources and operational management.On the clinical front Sophie Mégnien, MD, Chief Medical Officer, is stepping down from her current role. Pascal Birman to replace Sophie Mégnien, to ensure a seamless transition. Nadezda Mitrovic as new Head of Pharmacovigilance, brings to the company over 15 years of experience in clinical research and pharmacovigilance. Christine Roussarie after significant experience ranging from national regulatory agencies to biotechnology companies in the UK, Spain and France, has joined as new Head of Regulatory Affairs. Pascal Prigent, who joined the company in May 2018 as Executive Vice President Marketing and Commercial Development. Pascal also has been appointed Director of the Paris office.